Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where N. Selvakumar is active.

Publication


Featured researches published by N. Selvakumar.


Journal of Clinical Microbiology | 2001

Mutations in the rpoB Gene of Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates from India

Cheruvu Mani; N. Selvakumar; Sujatha Narayanan; P. R. Narayanan

ABSTRACT Mutations in the 81-bp rifampin resistance-determining region (RRDR) of the rpoB gene were analyzed by DNA sequencing of 50 Mycobacterium tuberculosis clinical isolates (44 resistant and 6 sensitive) from various parts of India. Fifty-three mutations of 18 different kinds, 17 point mutations and one deletion, were observed in 43 of 44 resistant isolates. Three novel mutations and three new alleles within the RRDR, along with two novel mutations outside the RRDR, are reported in this study.


Infection, Genetics and Evolution | 2011

Drug resistance among different genotypes of Mycobacterium tuberculosis isolated from patients from Tiruvallur, South India

Sivakumar Shanmugam; N. Selvakumar; Sujatha Narayanan

India continues to have the highest tuberculosis incidence, accounting for one fifth of the global incidence and 2/3rd of the cases in south East Asia. The TB burden is also augmented by multi drug resistance and HIV. Although inadequate and inappropriate treatment is responsible for drug resistance, pathogens genetic background may also play a role. The aim of this study was to understand the distribution of different genotypes of Mycobacterium tuberculosis in the Tiruvallur, rural area in South India and its association with drug resistance. A total of 1649 M. tuberculosis isolates were genotyped by IS6110 RFLP and spoligotyping. Drug susceptibility testing was done by minimum inhibitory concentration method (MIC) on all the samples. As reported earlier, the isolates with single and low copy IS6110 accounted for 66% among the 1649 M. tuberculosis strains genotyped. The majority (84%) of our strains belonged to the East African Indian (EAI) lineage, 28.6% to EAI3 sublineage and 19.5% to EAI5 sublineage. Rifampicin and streptomycin mono resistance followed by MDR (Multi-Drug Resistance, resistance to at least rifampicin and isoniazid) [(OR 0.2 [95%CI 0.11-0.46], P < 0.05)] were more common between Central Asian (CAS), T and Beijing compared to EAI lineage. In spite of the predominance of EAI lineage, its association with drug resistance was lower compared to the other genotypes prevalent in Tiruvallur, South India.


Infection, Genetics and Evolution | 2016

Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.

Ameeruddin Nusrath Unissa; Selvakumar Subbian; Luke Elizabeth Hanna; N. Selvakumar

Isoniazid (INH) is one of the most active compounds used to treat tuberculosis (TB) worldwide. In addition, INH has been used as a prophylactic drug for individuals with latent Mycobacterium tuberculosis (MTB) infection to prevent reactivation of disease. Importantly, the definition of multidrug resistance (MDR) in TB is based on the resistance of MTB strains to INH and rifampicin (RIF). Despite its simple chemical structure, the mechanism of action of INH is very complex and involves several different concepts. Many pathways pertaining to macromolecular synthesis are affected, notably mycolic acid synthesis. The pro-drug INH is activated by catalase-peroxidase (KatG), and the active INH products are targeted by enzymes namely, enoyl acyl carrier protein (ACP) reductase (InhA) and beta-ketoacyl ACP synthase (KasA). In contrast, INH is inactivated by arylamine N-acetyltransferases (NATs). Consequently, the molecular mechanisms of INH resistance involve several genes in multiple biosynthetic networks and pathways. Mutation in the katG gene is the major cause for INH resistance, followed by inhA, ahpC, kasA, ndh, iniABC,fadE, furA, Rv1592c and Rv1772. The recent association of efflux genes with INH resistance has also gained considerable attention. Interestingly, substitutions have also been observed in nat, fabD, and accD recently in resistant isolates. Understanding the mechanisms operating behind INH action and resistance would enable better detection of INH resistance. This information would aid novel drug design strategies. Herein we review all mechanisms known to potentially contribute to the complexity of INH action and mechanisms of resistance in MTB, with insights into methods for detection of INH resistance as well as their limitations.


BioMed Research International | 2015

Investigation of Ser315 Substitutions within katG Gene in Isoniazid-Resistant Clinical Isolates of Mycobacterium tuberculosis from South India

A. Nusrath Unissa; N. Selvakumar; Sujatha Narayanan; C. Suganthi; Luke Elizabeth Hanna

Mutation at codon 315 of katG gene is the major cause for isoniazid (INH) resistance in Mycobacterium tuberculosis (M. tuberculosis). Substitution at codon 315 of katG gene was analyzed in 85 phenotypically resistant isolates collected from various parts of southern India by direct sequencing method. The obtained results were interpreted in the context of minimum inhibitory concentration (MIC) of INH. Of the 85 phenotypically resistant isolates, 56 (66%) were also correlated by the presence of resistance mutations in the katG gene; 47 of these isolates had ACC, 6 had AAC, 2 had ATC, and one had CGC codon. The frequency of Ser315 substitution in katG gene was found to be higher (70%) amongst multidrug-resistant (MDR) strains than among non-MDR (61%) INH-resistant isolates. Further, the frequency of mutations was found to be greater (74%) in isolates with higher MIC values in contrast to those isolates with low MIC values (58%). Therefore, the study identified high prevalence of Ser315Thr substitution in katG gene of INH-resistant isolates from south India. Also, isolates harboring this substitution were found to be associated with multidrug and high level INH resistance.


Bioinformation | 2009

Insight to pyrazinamide resistance in Mycobacterium tuberculosis by molecular docking.

Amirudeen Nusrath Unissa; N. Selvakumar; Sameer Hassan

Pyrazinamide (PZA) - an important drug in the anti-tuberculosis therapy, activated by an enzyme Pyrazinamidase (PZase). The basis of PZA resistance in Mycobacterium tuberculosis was owing to mutation in pncA gene coding for PZase. Homology modeling of PZase was performed using software Discovery Studio (DS) 2.0 based on the crystal structure of the PZase from Pyrococcus horikoshii (PDB code 1im5), in this study. The model comprises of one sheet with six parallel strands and seven helices with the amino acids Asp8, Asp49, Trp68, Lys96, Ala134, Thr135 and Cys138 at the active site. Five mutants were generated with Gly at position 8, Thr at position 96, Arg at position 104, Tyr and Ser at position 138. The Wild-type (WT) and five mutant models were docked with PZA. The results indicate that the mutants Lys96Thr, Ser104Arg Asp8Gly and Cys138Tyr may contribute to higher level drug resistance than Cys138Ser. These models provide the first in-silico evidence for the binding interaction of PZA with PZase and form the basis for rationalization of PZA resistance in naturally occurring pncA mutant strains of M. tuberculosis.


Bioinformation | 2011

Binding of activated isoniazid with acetyl-CoA carboxylase from Mycobacterium tuberculosis

Ameeruddin Nusrath Unissa; Subramanian Sudha; N. Selvakumar; Sameer Hassan

AccD6 (acetyl coenzyme A (CoA) carboxylase), plays an important role in mycolic acid synthesis of Mycobacterium tuberculosis (Mtb). Induced gene expression by isoniazid (isonicotinylhydrazine - INH), anti-tuberculosis drug) shows the expression of accD6. It is our interest to study the binding of activated INH with the AccD6 model using molecular docking procedures. The study predicts a primary binding site for activated INH (isonicotinyl acyl radical) in AccD6 as a potential target.


International Journal of Antimicrobial Agents | 2008

Molecular analysis of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India

A. Nusrath Unissa; N. Selvakumar; Sujatha Narayanan; P. R. Narayanan


International Journal of Molecular and Clinical Microbiology | 2011

DETECTION OF ISONIAZID-RESISTANT CLINICAL ISOLATES OF MYCOBACTERIUM TUBERCULOSIS FROM INDIA USING SER315THR MARKER BY COMPARISON OF MOLECULAR METHODS

A. Nusrath Unissa; Sujatha Narayanan; C. Suganthi; N. Selvakumar


International Journal of Molecular and Clinical Microbiology | 2011

Virulence in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from south India

A. Nusrath Unissa; Sujatha Narayanan; N. Selvakumar


Archive | 2011

ELUCIDATING PYRAZINAMIDE RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS BY MOLECULAR DOCKING

A. Nusrath Unissa; S. Sudha; N. Selvakumar

Collaboration


Dive into the N. Selvakumar's collaboration.

Top Co-Authors

Avatar

Sujatha Narayanan

Indian Council of Medical Research

View shared research outputs
Top Co-Authors

Avatar

A. Nusrath Unissa

Indian Council of Medical Research

View shared research outputs
Top Co-Authors

Avatar

P. R. Narayanan

Indian Council of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Luke Elizabeth Hanna

Indian Council of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Sivakumar Shanmugam

Indian Council of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Selvakumar Subbian

Rutgers Biomedical and Health Sciences

View shared research outputs
Researchain Logo
Decentralizing Knowledge